GT Biopharma, Inc. GTBP
GT Biopharma, Inc. (Nasdaq: GTBP) is an oncology drug developer. Its lead program, GTB-3650, is in Phase 1 for relapsed/refractory CD33+ AML and high-risk MDS.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| GTB-3650 | R/R AML, high-risk MDS | protein/peptide | Phase 1 |
| GTB-5550 | solid tumors (B7-H3) | protein/peptide | Phase 1 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.